A lzheimer disease (AD) is the most common age-related neurodegenerative disease in the world. In the United States, ∼5.5 million individuals have dementia due to AD. AD is the sixth leading cause of death in the country. AD places a significant burden not only on persons affected by the disease, but also their families, with more than 15 million caregivers providing an estimated 18.2 billion hours of care in the year 2016. 1 The burden faced by caregivers is not only due to time sacrificed and the challenges of a progressive disease, but is also financial in nature and due to personal suffering.
Clinical diagnosis of AD is achieved by establishing the presence of progressive cognitive decline, while ruling out other causes of cognitive and functional impairment. 2, 3 The "gold standard" for definitive diagnosis of AD, however, is through discovering AD pathology during postmortem neuropathologic examination using widely accepted criteria. 4, 5 Recent studies have assessed the accuracy of clinical diagnosis in comparison with neuropathology at autopsy, demonstrating sensitivity of 70.9% to 87.3% and specificity of 44.3% to 70.8%. 6 Thus, while clinical data is often used to deduce underlying AD pathology, clinical diagnosis is not robustly accurate.
Current studies suggest that AD initially begins in a presympomatic phase with abnormal processing of β-amyloid (Aβ) peptide, leading to accumulation of amyloid plaques in the brain. This is followed by neuronal injury and degeneration, a tau-mediated process, accompanied by synaptic dysfunction, leading to eventual cognitive symptoms and the syndrome of dementia. 7 This model for AD pathophysiology has led to the consensus that biomarker evidence for brain amyloid deposition would enhance specificity in the diagnosis of AD. 2 In recent years, there have been many biomarker developments to assist in the diagnosis of AD. Of these, some of the most significant are positron emission tomography (PET) imaging ligands with strong affinity for Aβ plaques, allowing for in vivo visualization of AD pathology. [8] [9] [10] [11] [12] [13] [14] Diagnostic performance for these compounds was presented in the results of phase 3 trials demonstrating a median sensitivity of 92% and specificity of 95% for F 18 -Florbetapir, 10 a median sensitivity of 88% and specificity of 92% for F 18 -Florbetaben, 9 and a median sensitivity of 98% and specificity of 85% for F 18 -Flutemetamol. 14 A recent meta-analysis of F 18 -Florbetapir and F 18 -Florbetaben showed similar sensitivities and slightly lower specificities compared with those published in the phase 3 trials. 15 It is important to reiterate that the sensitivity and specificity values from the phase 3 trials are for the detection of amyloid plaques compared to autopsy tissues-not for the diagnosis of AD. Two other meta-analyses recently determined that amyloid imaging has 95% sensitivity and 57% specificity for predicting conversion from mild cognitive impairment to AD 16 and suggested that amyloid PET might be particularly useful in the diagnostic work-up of earlyonset dementia. 17 While these results suggest benefit in specific clinical circumstances, amyloid PET is not currently part of routine clinical care in the United States and recommendations for which patient populations would benefit the most from amyloid PET are being developed. Appropriate use criteria have been proposed that include persons with persistent or unexplained mild cognitive impairment, for those with atypical AD presentation or with suspected mixed etiology, and for those with progressive dementia with atypical early age of onset. 18 In 2013, the United States Centers for Medicare & Medicaid Services (CMS) released a statement that there is insufficient evidence that amyloid PET imaging improves patient outcomes and declined to provide reimbursement. 19 However, CMS did opt to provide coverage with evidence development, meaning that the procedure is only covered in the context of an approved clinical study. 19 This mechanism allows investigation into the utility of amyloid PET for diagnostically challenging clinical scenarios and to assist with clinical trials for treatment and prevention of AD. To date, several small single-center studies have suggested that amyloid imaging can affect diagnostic and treatment decisions. [20] [21] [22] [23] [24] [25] [26] A large, multicenter CMS funded study to examine the diagnostic and therapeutic benefits of amyloid imaging, its cost effectiveness, and its impact on patient outcomes is presently ongoing (ideas-study.org/).
While many studies have evaluated the diagnostic or prognostic implications associated with amyloid PET, few have explored its effects on the patient or caregiver. Not only may amyloid imaging help clinicians with their diagnosis and management, but it may also affect patient and caregiver decisions related to lifestyle and financial planning, longterm care, and employment. 18 Diagnostic uncertainty can lead to anxiety and depression among patients, which have been associated with negative quality of life outcomes for both patients and caregivers. 27 Receiving a diagnosis of AD and disease education has been shown to decrease such anxiety in patients 28 and to have positive effects on caregiver burden and depression. 21, 29 A few recent studies have qualitatively explored patient and caregiver views toward AD and mild cognitive impairment. 28, [30] [31] [32] So far, these studies have been small and none have directly explored patient and caregiver views toward amyloid PET imaging. A single small study involving 28 patients and 23 caregivers, which explored the impact of amyloid PET on patients and caregivers, demonstrated that caregivers appreciated the results of imaging and had an impact on their future plans. 21 Here, we report the largest sample analysis of patient and caregiver views toward amyloid PET imaging and its potential use in routine clinical practice.
METHODS

Study Design
Our data set consisted of 510 participants who answered 7 questions provided through an online questionnaire designed to obtain the thoughts and feelings of patients and caregivers. The questionnaire can be seen in Figure 1 . The vast majority of these participants (N = 487) were invited through the Alzheimer's Association TrialMatch mailing list, while others were directed to the questionnaire by the Indiana Alzheimer Disease Center website (N = 8), the 2015 FTD Caregiver Conference (N = 5), a family member (N = 3), or an unknown source (N = 7). Participants were informed that they are eligible for the study only if they or the person they provide care for had memory loss or dementia.
All participants were given a brief introduction about amyloid PET with an explanation that this type of imaging is currently FDA approved, yet does not have insurance coverage, and is not part of routine clinical care (Fig. 1) . Participants were given a 1 page questionnaire asking open-ended questions of their feelings about the lack of amyloid PET imaging in routine clinical diagnosis, whether they believed additional research on amyloid PET would be beneficial, and whether they would choose to pursue amyloid PET if offered the opportunity (Fig. 1) . In addition, participants were able to report whether they thought receiving a diagnosis early on through amyloid imaging would be beneficial for legal planning, financial advice, disability insurance, life insurance, long-term care insurance, communicating with family members, learning more about their diagnosis, or "other" scenarios. Finally, participants were asked to report how old they or the person they care for were when cognitive decline began and to provide their current city and state. Additional demographic information was not acquired in order to maintain confidentiality and anonymity ( Fig. 1 ).
Data Analyses
Answers to the questionnaire were recorded verbatim. We reviewed each participant's responses fully, then categorized the data for analyses. The question "How do you feel about the lack of amyloid PET imaging for diagnosis?" elicited a variety of responses, which were categorized as follows: (1) positive responses-responses stating amyloid imaging would be beneficial in patient care such as "If the PET scan is an effective tool …, then it should be covered by insurance and available to those effected by memory loss and other symptoms"; (2) emotionally charged positive responses-positive responses containing the words "alarming," "appalling," "angry," "cheated," "criminal" or "it's a crime," "disappointing," "discouraged," "disheartened," "feel bad," "feel sorry," "frustrated," "hate," "indignant," "not happy," "outraged," "petrified," "pitiful," "sad," "scary," "terrible," "travesty," "unfortunate," "upset"; (3) neutral responses-responses that were neither positive nor negative as in "I don't know enough about it to have an opinion"; and (4) negative responses-responses that were not supportive of this type of imaging such as "I understand why insurance doesn't feel it would be helpful."
Questions about participants' beliefs on whether further research into amyloid imaging would be beneficial, whether participants would choose to pursue amyloid imaging if offered the opportunity, and whether receiving an early diagnosis would be beneficial for the various scenarios were not further categorized.
While we did not specifically ask whether the respondent was a patient or a caregiver, 63.3% of the respondents provided that information in their answers (ie, "I was 54 when my doctor broke the news …" vs. "my mother was diagnosed with Alzheimer …"). This allowed for the dichotomization of patient versus caregiver status in 323 of our 510 cases.
Responses were also divided by self-reported age of onset of cognitive decline as early-onset (below age 65) or late-onset (65 and older).
Geographically we divided responses as coming from urban versus rural area based on the US Department of Health and Human Services, 2013 National Center for Health Statistics Urban-Rural Classification Scheme 33, 34 and by US regions (ie, Northeast, Midwest, South, and West) based on the US Census Bureau region classification. 35 
Statistical Methods
We used Pearson χ 2 tests to compare response data between (1) patients and caregivers, (2) early-onset and lateonset cases, (3) urban and rural residents, and (4) US geographic regions. When analyzing data by US regions, in order to determine which particular regions were driving the statistical significance in various scenarios, standardized Pearson residuals were determined. 36 All statistical analyses were done with IBM SPSS Statistics 24. Analyses of the study responses among the different groups were performed on the data that could be assigned to the specific divisions, leaving unknown data out of the analysis.
RESULTS
Sample Characteristics
Our data set consisted of 510 total participants. The responses were categorized as 87 (17.1%) patients and 236 (46.2%) caregivers. We were unable to assign 187 (36.7%) of the responses to a participant category due to missing information. On the basis of age when cognitive decline began, 215 (42.2%) were categorized as early-onset and 270 (52.9%) were categorized as late-onset. Twenty-five (4.9%) were unassigned as these participants did not provide an answer for the age on onset. Geographically, 446 (87.4%) of responses were from urban areas while 59 (11.6%) of responses were from rural areas. Divided by US region, the responses were categorized as 83 (16.2%) Northeast, 114 (22.4%) Midwest, 182 (35.7%) South, and 119 (23.3%) West. Five (1.0%) participants did not provide their current city and state, and so these responses were not assigned to the urban versus rural division of responses. An additional 7 participants were from locations in Canada, Greece, and the Dominican Republic and so a total of 12 (2.4%) of responses were unassigned when dividing responses by US regions. Forty-eight US states (not included: Rhode Island and Wyoming), 2 Canadian provinces (British Columbia and Ontario), and cities in the Dominican Republic (Santiago) and Greece (Athens) were represented among the responses provided.
Additional analysis of the data showed that there were significantly more patients versus caregivers among earlyonset (44.2% patients vs. 55.8% caregivers) than late-onset cognitive decline (12.6% patients vs. 87.4% caregivers), P < 0.0001. There were no significant differences between the number of patients versus caregivers or early-onset versus late-onset participants when analyzed by urban versus rural or US regional distributions. When participants were asked whether they believed additional research on amyloid PET would be beneficial, 507 (99.4%) responded yes. A large number of responders, 508 (99.6%), also stated they would choose to pursue amyloid PET if offered the opportunity. The majority cited the benefit of having definitive diagnosis as the reason for pursuing amyloid imaging. Interestingly, all 9 responders who felt the absence of insurance coverage for amyloid PET is justifiable stated that they would pursue an amyloid PET scan if recommended by their doctor.
Questionnaire Results
Early diagnosis obtained through amyloid imaging was thought to be beneficial for legal planning by 446 (87.5%), for financial advice by 392 (76.9%), for disability insurance by 306 (60.0%), for life insurance by 250 (49.0%), for longterm care insurance by 345 (67.6%), for communicating with family members by 467 (91.6%), for learning more about their diagnosis by 474 (92.9%), and for "other" scenarios by 123 (24.1%) participants. Seventy-six of the 123 "other" responses simply restated one or more of the options that were already listed. Forty-six were new items. Another 12 subjects made comments in this field that listed other benefits without checking the box "other." The additional benefits among these 58 new responses consisted of eligibility for participation in clinical trials (26%), starting early treatment (21%), focusing on "enjoying life" (17%), adjusting/adapting to diagnosis (12%), participation in support groups (7%), decreased anxiety and stress (5%), engaging in spiritual pursuits (3%), increasing one's awareness of his/her cognitive problems (3%), participation in brain donation program (2%), modifying home to meet one's needs (2%) and aggressively addressing any other health issues (2%). An additional 16 participants voiced concerns with amyloid PET affecting their ability to sign up for long-term care and life insurance. Tables 2-5 describe the distribution of responses in our subgroup analyses. No significant differences were present among patients versus caregivers, early-onset versus lateonset cognitive decline, urban versus rural locations, or among US regions regarding their reaction to the unavailability of amyloid imaging in clinic (Table 2) , their perceived need for additional research on amyloid PET (Table 3) and their willingness to subject themselves to amyloid imaging if recommended by their doctor (Table 4 ). There were no significant differences between patients versus caregivers or urban versus rural subgroups in terms of their intent to pursue more information about the disease, legal and financial planning, to explore their options for disability, long-term care and life insurance, and to communicate their diagnosis and prognosis with their families (Table 5) . Those with earlyonset cognitive decline were more likely to indicate they would utilize information from amyloid imaging to explore their options for disability insurance than those with lateonset cognitive decline (66.0% early-onset vs. 54.8% lateonset, P = 0.03), however these groups did not differ in terms of the other long-term planning scenarios (Table 5) .
Among the data divided by US region, significant differences were found among participants in utilizing information from amyloid imaging for legal planning (88.0% Northeast vs. 93.0% Midwest vs. 86.3% South vs. 84.0% West, P = 0.02), for disability insurance (67.5% Northeast vs. 67.5% Midwest vs. (Table 5 ).
DISCUSSION
Our data suggest that most patients and caregivers believe amyloid imaging would be beneficial in patient care. The majority of participants had positive responses for the use of amyloid imaging in clinical practice, with many reflecting strong emotional feelings such as frustration, anger, and disappointment for the lack of amyloid imaging in routine clinical practice in the absence of insurance coverage. Few participants had neutral feelings about the lack of imaging often stating they needed more information to give a thoughtful answer. Even fewer participants were comfortable with the current unavailability of amyloid PET in the clinic, frequently explaining that without any diseasemodifying therapies available for AD, amyloid imaging may have no therapeutic benefit. Nearly all participants believed additional research into amyloid PET imaging would be beneficial and would pursue amyloid imaging if recommended by their doctor, with most responders citing the benefit of having a definitive diagnosis as their reason for pursuing the test. Surprisingly, of those participants who had neutral feelings about the lack of amyloid imaging (N = 51, 10.0%), 49/51 (96.1%) stated they would pursue amyloid imaging if given the opportunity. The 2 subjects who said that at this time they will opt out from amyloid imaging cited lack of treatment as the reason behind refusing to subject themselves to this diagnostic imaging modality. All participants who were comfortable with the lack of coverage of amyloid PET at this time (N = 9, 1.8%) nonetheless stated they would pursue amyloid imaging if offered.
Receiving amyloid PET results was believed to be most beneficial for learning more about the diagnosis, communicating with family, and legal planning followed by financial planning, purchasing long-term care, disability, and life insurance, and other reasons such as finding support groups, establishing home care, and participating in clinical trials. Interestingly, no significant differences were found in responses from patients versus caregivers or from urban versus rural responders. However, significantly more responders with early-onset cognitive decline were likely to use information from amyloid imaging to explore options for disability insurance than responders with late-onset cognitive decline. The likely explanation for this is that younger patients and their caregivers are more likely to be still involved with their careers or are not yet eligible for Medicare or as financially established as some of their older counterparts.
In terms of US regional differences, we found that significantly more responders from the Midwest would utilize information from amyloid imaging for legal planning, disability, and life insurance than the other regions, particularly the South and the West. The US Census Bureau reports that the rate of educational attainment (High School or greater education) is highest in the Midwest, followed by the Northeast, West, and then the South. 37 In regards to health insurance coverage, the US Census Bureau also reports that the uninsured rate is lowest in the Northeast and Midwest, followed by the West, and then the South. 38 It is possible that these trends serve as an explanation for why participants from the Midwest were more likely to use information from amyloid imaging for the various life planning scenarios compared with other regions.
We observed significantly more patients versus caregivers among those with early-onset than among those with late-onset cognitive decline. There could be several reasons for this imbalance. It is possible that persons with earlyonset cognitive decline have greater emotional connection with their disease given the timing of onset and are thus more inclined to participate in studies such as ours. Among those with late-onset cognitive decline, perhaps the caregivers, heavily burdened by financial and time-intensive sacrifices, are more emotionally involved and thus more inclined to participate. It is also possible that the older patients are simply less inclined to use a computer and be digitally subscribed to TrialMatch compared with their younger counterparts. Regardless, it is important to note that were no significant differences in the responses between patients and caregivers from the early-onset versus the lateonset groups.
Several strengths and limitations of our study are worth discussing. Patients and caregivers were invited to participate only if they or the ones they provide care for were affected by memory loss or dementia. No further participation restrictions were used and no objective verification of a diagnosis of cognitive decline was made. Thus, responses from participants not affected by dementia and more specifically AD may have been included and could have impacted our results. In our questionnaire, the only demographic questions asked were related to current location and age of onset for cognitive decline. While we limited demographic information to lessen the burden of taking part in the study and to also maintain confidentiality and anonymity, additional participants' characteristics such as age, sex, race, education level, socioeconomic status, and patient/ caregiver status may have been helpful to further understand participants' views on amyloid imaging. We do not know how the omission of these questions may have affected trends among different groups. Additional limitations may include the presurvey information and phrasing of the questions, which may bias toward a positive response to amyloid imaging; and response bias from those who are more in favor of the technique being more likely to respond to the survey questions. AD has a significant impact among both patients and caregivers. Clinical diagnosis of AD shows moderate accuracy, even among experts in the field. Amyloid PET imaging has demonstrated significant promise for improving diagnostic accuracy. While the value of amyloid PET toward improving patient outcomes remains debated, ongoing research studies will likely influence payers' coverage decisions related to this imaging modality as well as its incorporation into clinical care in the United States. It will be important to not only consider the impact of amyloid PET on diagnosis, treatment, and patient outcomes, but also on how it harmonizes with the values of patients and caregivers themselves. Our data suggest that patients and caregivers feel that amyloid PET imaging would be beneficial in clinical practice and that additional research into amyloid imaging would be useful. They would also tend to pursue amyloid imaging if presented the opportunity and believe that diagnosis assisted by such imaging would be useful for various long-term planning scenarios ranging from legal planning to participation in clinical trials. Factors such as geography, education, and health insurance coverage may also play a role with decisions for future planning. Further studies will be needed to thoroughly assess the value of amyloid imaging in the lives of patients and caregivers and to understand its impact from their perspective. 
